Company Description
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer.
The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome.
In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo.
It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation.
Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 1996 |
| IPO Date | Nov 29, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 164 |
| CEO | Raul Rodriguez |
Contact Details
Address: 611 Gateway Boulevard, Suite 900 South San Francisco, California 94080 United States | |
| Phone | 650 624 1100 |
| Website | rigel.com |
Stock Details
| Ticker Symbol | RIGL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001034842 |
| CUSIP Number | 766559702 |
| ISIN Number | US7665597024 |
| Employer ID | 94-3248524 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Raul R. Rodriguez | President, Chief Executive Officer and Director |
| Dean L. Schorno CPA | Executive Vice President and Chief Financial Officer |
| Raymond J. Furey J.D. | Executive Vice President, Chief Compliance Officer, General Counsel and Corporate Secretary |
| David A. Santos | Executive Vice President and Chief Commercial Officer |
| Dr. Lisa Rojkjaer M.D. | Executive Vice President and Chief Medical Officer |
| Julie Patel | Senior Vice President of Human Resources |
| Joseph Lasaga | Executive Vice President and Chief Business Officer |
| Tarek Sallam | Vice President of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |
| Apr 10, 2025 | ARS | Filing |
| Apr 10, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 10, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 10, 2025 | 8-K | Current Report |
| Mar 4, 2025 | 8-K | Current Report |
| Mar 4, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 11, 2025 | SCHEDULE 13G/A | Filing |